Loading...
01/11 03:08
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents mixed signals: a slight revenue increase, but a significant net loss and decreased EBITDA. The Q&A highlights potential growth in aseptic manufacturing and a new GLP-1 agreement, but lacks clarity on specifics. Despite strategic partnerships and future growth potential, current financials and unclear guidance temper expectations, leading to a neutral sentiment.
Revenue for Q4 2025 $36.4 million, a decrease of 4% year-over-year. The decrease was primarily due to a $5.6 million decrease in CDMO revenues, impacted by $4.4 million of lower development revenue due to the completion of a discrete development project in the prior comparable period and timing of customer project life cycles. However, hyaluronic acid manufacturing revenues increased by $4.1 million due to increased demand from the largest customer supply chain initiatives.
Gross Profit for Q4 2025 $14 million, a decrease of $3.3 million year-over-year. The decline was primarily due to a $6 million decrease in CDMO gross profit, impacted by sales mix, including lower development revenue and aseptic manufacturing volumes. This was partially offset by a $2.8 million increase in HA manufacturing gross profit due to increased volumes and manufacturing variances.
Selling, General and Administrative (SG&A) Expenses for Q4 2025 $9 million, a decrease of $3.2 million year-over-year. The decrease was primarily due to $1.6 million of lower legal, personnel, and finance and accounting consulting expenses as a result of focused efforts to reduce operational expenses and bring in new leadership.
Net Loss for Q4 2025 $1.1 million, compared to a net loss of $7.1 million in the same period last year. The improvement was due to reduced SG&A expenses and other non-operating income or expense items.
Adjusted EBITDA for Q4 2025 $9.1 million, a decrease of $1.3 million year-over-year. The decrease was primarily due to the decrease in gross profit, partially offset by favorable recurring SG&A expenses.
Revenue for Fiscal Year 2025 $128.9 million, an increase of 0.5% year-over-year. The increase was due to a $7.1 million increase in HA manufacturing demand, primarily from the largest customer supply chain initiatives. This was partially offset by a $6.5 million decline in CDMO revenues, primarily due to $6.2 million of lower development revenue from the completion of a discrete development project in the prior comparable period and timing of customer project life cycles.
Gross Profit for Fiscal Year 2025 $40.3 million, a decrease of $1.6 million year-over-year. The decrease was due to a $5.9 million decrease in CDMO gross profit, impacted by sales mix, including lower development revenue and aseptic manufacturing volumes. This was partially offset by a $4.3 million increase in HA manufacturing gross profit due to increased volumes and manufacturing variances.
Selling, General and Administrative (SG&A) Expenses for Fiscal Year 2025 $44 million, an increase of $3.5 million year-over-year. The increase was primarily due to a $3.7 million increase in non-cash stock-based compensation, mostly related to new higher performance stock unit grants to the company's executive officers.
Net Loss for Fiscal Year 2025 $38.7 million, compared to a net income of $12 million in the prior year. The loss included a $7.7 million loss on the sale or disposal of assets, while the prior year included a favorable $39.5 million non-cash fair market value adjustment to the debt derivative liability.
Adjusted EBITDA for Fiscal Year 2025 $19.5 million, a decrease of $0.7 million year-over-year. The decrease was primarily due to the decrease in gross profit.
New Development Agreements: Signed multiple new development agreements with new and existing customers, including 9 new programs with 9 new customers. Subsequent wins include a late-stage clinical GLP-1 program.
Late-Stage Pipeline Progress: Signed a 10-year commercial manufacturing and supply agreement for a novel ophthalmic therapeutic drug. Advanced other late-stage programs, including a significant injectable medical device product.
New Early-Stage Programs: Added 3 new early-stage programs in respiratory disease and ophthalmology, including a partnership with Humanetics for the BIO 300 program.
Geographic Expansion: Expanded operations to include Asia Pacific markets, supported by a strong quality system and regulatory compliance framework.
Productivity Improvements: Achieved record output in the fermentation department and improved on-time delivery rate to 97%.
ERP System Implementation: On track to launch a new cloud-based ERP system in Q1 2026 to enhance efficiency, inventory control, and financial management.
Workforce Optimization: Rightsized workforce, improved productivity, and reduced expenses as a percentage of revenue.
Strategic Plan Execution: Focused on maximizing existing customer business, advancing late-stage programs, and winning new impactful business.
Leadership Changes: Appointed new leaders, including a CFO, Senior VP of Operations, Chief Legal Officer, and Chief Commercial Officer, to enhance operations and business development.
Revenue Decrease: Revenues for the 3 months ended May 25, 2025, decreased by 4% compared to the prior year period, primarily due to a $5.6 million decrease in CDMO revenues, which was impacted by lower development revenue and timing of customer project life cycles.
Gross Profit Decline: Gross profit for the 3 months ended May 25, 2025, declined by $3.3 million compared to the same period last year, primarily due to a $6 million decrease in CDMO gross profit, which was impacted by sales mix and lower development revenue.
Net Loss: The company recorded a net loss of $1.1 million for the 3 months ended May 25, 2025, compared to a net loss of $7.1 million in the prior year period. For the 12 months ended May 25, 2025, the company reported a net loss of $38.7 million, a significant decline from net income of $12 million in the prior year.
CDMO Revenue Challenges: CDMO revenues declined by $6.5 million for the 12 months ended May 25, 2025, due to lower development revenue and timing of customer project life cycles, which could impact future financial performance.
Operational Efficiency Risks: While the company has made progress in improving operational efficiency, the ongoing implementation of a new ERP system and organizational restructuring could pose risks to operational stability and cost management.
Regulatory and Commercialization Risks: Many late-stage pipeline programs are poised for potential regulatory approval and commercialization by 2028, but there is no guarantee they will reach the finish line, posing risks to midterm growth projections.
Customer Dependency: The company remains heavily reliant on existing customers for growth, with a significant inflection point tied to one customer in 2027. This dependency could pose risks if customer commitments or market conditions change.
Supply Chain and Manufacturing Risks: The company faces risks related to supply chain disruptions and manufacturing challenges, as evidenced by the variability in CDMO and HA manufacturing revenues.
Financial Guidance Uncertainty: The company has provided financial guidance for a 7-month transition period but cautioned against extrapolating these results, indicating uncertainty in future financial performance.
Revenue Growth: The company expects to achieve a 12% revenue compound annual growth rate (CAGR) over the midterm.
EBITDA Margins: The company aims to increase EBITDA margins to more than 25% over the midterm.
Customer Expansion: A significant inflection point is expected in 2027 with a current customer, including increased minimum take-or-pay commitments and expansion into Asia Pacific markets.
Late-Stage Pipeline Commercialization: Many late-stage pipeline programs are poised for potential regulatory approval and commercialization by 2028, with even a modest subset expected to generate substantial growth.
New Commercial Agreements: A new 10-year commercial manufacturing and supply agreement has been signed for a novel ophthalmic therapeutic drug, including multimillion-dollar CDMO services to advance the program.
New Programs: Nine new programs were added in fiscal 2025, spanning various modalities, with additional agreements signed post-quarter, including a late-stage GLP-1 therapeutic for obesity and a Phase II dermatology program.
Operational Enhancements: The company plans to launch a new enterprise resource planning (ERP) system in Q1 2026 to enhance efficiency, inventory control, financial management, and cost reduction.
Transition Period Guidance: For the 7-month transition period ending December 2025, revenue is expected to be between $74 million to $76 million, with adjusted EBITDA in the range of $12 million to $14 million.
The selected topic was not discussed during the call.
The earnings call summary indicates strong financial metrics with improved net loss and EBITDA, alongside strategic advancements like new commercial agreements and operational enhancements. The Q&A reveals positive sentiment from analysts, especially regarding cost reductions and revenue upticks. Despite some unclear responses, the overall guidance and strategic plans, including a commercial win and collaboration opportunities, suggest positive momentum. Thus, the stock is likely to experience a positive movement in the short term.
The earnings call summary presents mixed signals: a slight revenue increase, but a significant net loss and decreased EBITDA. The Q&A highlights potential growth in aseptic manufacturing and a new GLP-1 agreement, but lacks clarity on specifics. Despite strategic partnerships and future growth potential, current financials and unclear guidance temper expectations, leading to a neutral sentiment.
The earnings call reveals a mixed financial performance with a net loss and decreased revenues. Despite some positive indicators like operational improvements and increased HA manufacturing demand, challenges such as increased SG&A expenses, supply chain issues, and litigation costs persist. The Q&A section did not provide sufficient clarity on key issues, and the absence of a share repurchase program further dampens sentiment. While there is optimism around future growth and cash flow improvements, the current financial struggles and uncertainties result in a negative outlook for the stock price.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
